LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

@article{Schuler2012LUXLung3A,
  title={LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.},
  author={Martin H Schuler and Nobuyuki Yamamoto and Kenneth J O'byrne and Vera Hirsh and Tony Shu Kam Mok and Sarayut Lucien Geater and Sergey V Orlov and Chun-Ming Tsai and Michael J. Boyer and W C Su and Jaafar Bennouna and Terufumi Kato and Vera A Gorbunova and Ki Hyeong Lee and Riyaz N H Shah and Dan Massey and Robert M. Lorence and Mehdi Shahidi and Lecia V Sequist},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 18_suppl},
  pages={LBA7500}
}
LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the efficacy and safety of A compared with pemetrexed/cisplatin (PC) in pts with EGFR mutation positive advanced lung adenocarcinoma. METHODS Following central testing for EGFR mutations (companion diagnostic TheraScreen EGFR RGQ PCR kit), 345 pts (stage IIIB/IV, PS 0-1, chemo-naive) were randomized 2:1 (A: 230; PC: 115… CONTINUE READING
78 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 78 extracted citations

Similar Papers

Loading similar papers…